



Graphenano Medical Care and Kern Pharma will develop an oral treatment with graphene to reduce obesity

Preclinical studies conducted by Graphenano Medical Care, based in the Technology Park of the University of Alcalá, indicate a 25% weight reduction with this therapy, which functions as an intestinal fat adsorbent.

Kern Pharma will be responsible for the regulation, compliance, and human trials of this medical device, which would be available for purchase over the counter at pharmacies without a prescription.

Alcalá de Henares, June 19, 2023.- Graphenano Medical Care, headquartered in the Technology Park of the University of Alcalá, and pharmaceutical company Kern Pharma have reached an agreement to develop an oral treatment with medical-grade graphene to reduce obesity.

Preclinical studies managed by Graphenano Medical Care, under conditions of high fat intake, indicate "a 25% weight reduction thanks to this therapy, which functions as an intestinal fat adsorbent without any side effects," according to the company's scientific manager, Diego Rodríguez.

Rodríguez has explained that "graphene and dietary fat reach the digestive tract together, and in the small intestine, part of the fat adheres to the graphene." "Its mechanism of action would be adsorption, and only the fat that has not bound to the graphene would enter the bloodstream, which means much less, resulting in less weight gain," he emphasized.

Following the success of the preclinical studies conducted over the past four years, which led to the patent application in 2020, Kern Pharma will now be responsible for the regulation, compliance, and human trials. Based on Rodríguez's statements, the treatment would fall into the category of a medical device and could be purchased at pharmacies without a prescription.

A material with multiple applications

Graphene is a material with numerous applications in various fields, such as medicine, construction, or the dental sector. In the case of medicine and cosmetics, the graphene used "is pure carbon, free from contaminants, obtained through proprietary processes and organic gases," according to the scientific manager of Graphenano Medical Care.

About Graphenano Medical Care

Graphenano Medical Care is one of the divisions of Graphenano Nanotechnologies, a company founded in 2012 in Yecla (Murcia) by the Martín and José Antonio Martínez brothers. The company has different subsidiaries, including Smart Materials, Dental, Composites, Medical Care, and Additives.

The medical division has its own research group at the University of Alcalá, led by Dr. Manuel Rodríguez and Dr. Diego Rodríguez. Their aim is to develop biomedical and cosmetic applications based on the exceptional properties of graphene and its derivatives. Graphenano Medical Care is the first company worldwide to patent a type of graphene for medical and aesthetic use.

For further information and/or interview management, you can contact:

Europa Press Comunicación

Àgata Sala agatasala@europapress.es / 600 90 55 38

Isana Navarro isananavarro@europapress.es / 600 90 55 65